Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

According to court documents, the lawsuits focus on Moderna's use of lipid nanoparticle encapsulation of mRNA vaccines, a technology used to protect the mRNA molecules as they are delivered to ...

Meanwhile, Alnylam has filed suit against both Pfizer/BioNTech and Moderna in the US, alleging that both their vaccines infringe patents it holds on lipid nanoparticles used to deliver them in the ...

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Notable examples include the Pfizer-BioNTech and Moderna vaccines, which rely on lipid nanoparticles (LNPs) for mRNA protection and cellular uptake, and hepatitis B vaccines, which use virus-like ...

March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ... against Moderna, Inc. and certain ...

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized. About half of ...